The Global Health Body Issues Alert Over Severe Lack of Weight-Loss Injections
Under one in 10 individuals that would benefit from weight-loss injections such as Wegovy are able to get them, states the global health agency as it publishes its first recommendations on the therapies.
With more than one billion individuals worldwide currently living with obesity, it is advocating for more widespread and fairer availability to this class of drugs.
Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The latest guidance affirms that excess weight is a long-term condition that can be managed with thorough and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major barriers to broad availability to the jabs that can help people shift considerable weight, explains the body.
GLP-1 Therapy Scarcity
Despite the current most favorable outlook, the supply of such drugs would only suffice for about 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline urges nations and manufacturers to expand access, by measures such as voluntary licensing.
The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in several nations in 2026.
How Obesity Jabs Operate
The injections imitate a natural hormone to slow digestion, suppress the appetite and boost satiety so users consume fewer calories.
People typically see weight reduction after several weeks of commencing the once-weekly jabs.
Evidence points to users may see weight return within a year of halting the medication, because their usual appetite return.
To be overweight or obese raises your chance for contracting diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight concerns people in every country and was associated with over three and a half million deaths worldwide in 2024, per the health agency.
